NCT04876716View on ClinicalTrials.gov

Azole-echinocandin Combination Therapy for Invasive Aspergillosis

PHASE3TerminatedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 11, 2021

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2024

Conditions
Invasive Aspergillosis
Interventions
DRUG

Azole

Dosing according to the SPC

DRUG

Anidulafungin

200mg loading dose on day 1 and 100mg QD thereafter

Trial Locations (4)

Unknown

UZ Ghent, Ghent

UZ Leuven, Leuven

Radboud Universitair Medisch Centrum, Nijmegen

3000 CA

Erasmus Medical Center (EMC), Rotterdam

Sponsors
All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Stichting Hemato-Oncologie voor Volwassenen Nederland

OTHER

lead

Erasmus Medical Center

OTHER

NCT04876716 - Azole-echinocandin Combination Therapy for Invasive Aspergillosis | Biotech Hunter | Biotech Hunter